Welcome to the online course covering the use of Minimal (measurable) Residual Disease in the management of patients with Acute Myeloid Leukaemia.
By the end of this course, you will have a comprehensive understanding of the subject and the knowledge and skills required to practice in this field confidently.
You will work through the following sections:
1. Introduction and objectives
2. Overview of MRD techniques in AML and current recommendations
3. MRD for selection of intermediate-risk patients for transplant
4. Pre-transplant MRD and choice of transplant conditioning
5. Treatment of MRD relapse with targeted agents
6. Emerging use of NGS-MRD to detect FLT3 mutations
We will use video tutorials with English captions and an end-of-course assessment that awards a certificate upon successful completion.
It is estimated this course will take you 1 hour to complete.
The target audience for this course are:
- Biomedical scientists/medical laboratory scientists
- Haematology trainees and consultants
- Haematopathology trainees and specialists
Your course certificate will be available for download after successfully completing the course assessment. If you have difficulty downloading your certificate, please email email@example.com for further assistance.
About our tutor
Dr Richard Dillon
Dr Richard Dillon is a Clinical Senior Lecturer in Cancer Genetics in the Department of Medical & Molecular Genetics, School of Basic & Medical Biosciences, at King's College London and Consultant Haematologist at Guy’s Hospital. Dr Dillon leads a research group focussed on Acute Myeloid Leukaemia (AML). The group uses advanced molecular techniques to refine outcome prediction and personalise treatment for patients with AML.